Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Northern Capital Management LLC boosted its position in shares of Advaxis Inc. (NASDAQ:ADXS) by 6.0% during the third quarter, Holdings Channel reports. The institutional investor owned 18,125 shares of the biotechnology company’s stock after buying an additional 1,025 shares during the period. Northern Capital Management LLC’s holdings in Advaxis were worth $194,000 at the end of the most recent reporting period.
Several other large investors have also recently made changes to their positions in ADXS. Bank of New York Mellon Corp raised its stake in shares of Advaxis by 34.3% in the third quarter. Bank of New York Mellon Corp now owns 220,691 shares of the biotechnology company’s stock worth $2,359,000 after buying an additional 56,323 shares in the last quarter. Tocqueville Asset Management L.P. raised its stake in shares of Advaxis by 32.2% in the third quarter. Tocqueville Asset Management L.P. now owns 71,300 shares of the biotechnology company’s stock worth $762,000 after buying an additional 17,350 shares in the last quarter. Bank of Montreal Can raised its stake in shares of Advaxis by 2.2% in the third quarter. Bank of Montreal Can now owns 79,542 shares of the biotechnology company’s stock worth $850,000 after buying an additional 1,735 shares in the last quarter. Koshinski Asset Management Inc. purchased a new stake in shares of Advaxis during the third quarter worth about $156,000. Finally, Fox Run Management L.L.C. purchased a new stake in shares of Advaxis during the third quarter worth about $175,000. 59.06% of the stock is owned by hedge funds and other institutional investors.
I ran across this. See if it sounds like a stock you know.
Creativity Manipulation in Stock Trading:
Unchecked Creativity Manipulation results are disastrous. Natural trade does create windows through trade action by the buy and sell process, but devious manual or electronic trade can also create widen spread windows. These actions are designed to delay and stall gains for direct ASK PPS lowering. These trade actions are the result of owner relinquishment and harm stock funded corporations and long term investors.
Creativity Manipulation widen spread windows allow any trader the ability to insert a Bid or ASK order into the current spread page. ASK lowers the owners present higher Price per Share (PPS) and Bid increases buyers cost. Both actions tighten the spread, but the ASK lowering removes the ASK PPS rise of the share owner’s ASK gains.
All successful corporations monitor processes to determine a fault in system operations. Creativity Manipulation thrives in an environment without monitors. Financial areas of service are susceptible due to the quick monetary gains achieved. The key for successful observation is correct monitor placement. A monitor system for data formulation must exist. This capture of data allows the production of numbers to provide statistics.
We request the placement of a Monitor System be used to gather data to provide numbers to produce statistics by share relinquishment. We request the placement of a Monitor System to be used to gather data on trade actions of received shares to owners with the right to relinquish. We request a Monitor System to gather data of ASK orders to relinquish shares be placed on page levels. These three areas would establish patterns and provide the tools to prosecute abuse.
Conclusion:
Share relinquishment manipulation controls the current ASK PPS an example would be Mannkind Corporation (MNKD). We the owners and long term investor need to know who placed these relinquish ASK sell orders. We feel this to be an aid in the establishment of Creativity Manipulation patterns. A tool for those who oversee the market to preserve wealth and gain for the stock funded corporation and supportive investor allowing evidence for illegal trade and prosecution.
Creativity Manipulation Trade cost the manipulator very little, they obtain most of their invested value after sell and sometimes with gain. The dedicated stock owner must buy or find new owners to create price rise to preserve their previous stock share value. The cycle of relinquishment to sell and repurchase harm and destroy corporations. Communities suffer from lost enterprise being destroyed. These actions remove the dream of pursuit of happiness to many American families by capital loss. A corporation failure forced by individuals seeking private gain.
Link:
https://www.change.org/p/the-current-stock-market-stock-share-relinquishment-sale-and-order-placement-data-tracked?recruiter=537191234&utm_source=share_petition&utm_medium=copylink
Where did you find info?
I am going. The tickets are free. Anyone else?
Cover Cover... How fast can you cover?
I say the bottom is in.
New SA Article mentions ADXS: Title: On High Drug Prices, Gouging, And Senator Bernie Sanders.
ADXS point: On the other hand, when news like this comes down the pipe, I see potential opportunity. Advaxis (NASDAQ:ADXS), for example, has been in a steep decline on the back of news that Aduro Biotechnology (NASDAQ:ADRO) had a clinical hold placed on its clinical trial. In the meantime, Advaxis presented encouraging clinical trial data.
Disclosure: I am/we are long ADXS.
Link:
http://seekingalpha.com/article/4016243-high-drug-prices-gouging-senator-bernie-sanders
Great Article on Immunotherapy and recent successes.
Check out the videos as well...
http://www.cnn.com/2016/10/26/health/immunotherapy-cancer-treatments/index.html?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+rss%2Fcnn_health+%28RSS%3A+CNN+-+Health%29
I believe they are saying they do Investment Business with ADXS and receive a fee for some of their work. I do not think that has anything to do with raising capital for the company. I found it a good source of where things stand today with some projected milestones. I believe it is unbiased. Their summation is not a ringing endorsement:
Risk to Invesment
We consider an investment in Advaxis to be a high-risk investment. Advaxis is a development stage company with no history of taking
a treatment to market and currently has no FDA-approved drugs in its portfolio. The Company’s lead program has not yet entered
Phase III trials. Furthermore, early indications of efficacy do not necessarily translate into positive late-stage results. Phase III clinical
trials will result in significant additional expenses to the Company and may require additional rounds of dilutive financing. As with any
company, Advaxis may be unable to obtain sufficient capital to fund planned development programs. There are regulatory risks associated
with the development of any drug, and Advaxis may not receive FDA approval for its candidates despite significant time and financial
investments. Regulatory approval to market and sell a drug does not guarantee that the drug will penetrate the market, and sales may
not meet expectations.
Excellent Analysis from LifeScience:
http://baystreet.ca/articles/research_reports/lifesci/Advaxis102516.pdf
In case you ever wondered what's on the line here with ADXS-PSA for prostate cancer...
Competitive Market: (from Investopeda)
If approved, Advaxis' ADXS-PSA drug will compete against Johnson & Johnson’s (JNJ) Zytiga drug, which received FDA approval in 2011 to treat late-stage prostate cancer. Zytiga generated revenue of $2.2 billion in 2015.
The ADXS-PSA drug will also compete with Xtandi, another mCRPC drug jointly developed by Medivation Inc. and Astellas Pharma. Xtandi generated 2015 revenues of $1.15 billion in the United States.
The global market for prostate cancer treatment is estimated to top $13.6 billion by 2021. (See also: Advaxis to Get $2.7 Million NOL Tax Credit.)
Metastatic castration-resistant prostate cancer (mCRPC) is an advanced form of prostate cancer. The standard treatment for prostate cancer involves surgery and radiation therapy. Each year, 35,000 new mCRPC cases are diagnosed in the United States.
http://www.investopedia.com/news/advaxis-prostate-cancer-study-moves-forward-adxs/?partner=YahooSA&yptr=yahoo
How is it that we always have a Red day when Options are expiring? Coincidence?
Time the Shorts ran for cover...
One thing not being considered in all this Dilution Dan talk is what he did not give away. He did not strike early deals with just any BP to get that upfront cash (and to some extent- instant product credibility). That of course, sacrifices a lot of return when the product is proven. And of course, that only leaves 2ndary offers for raising cash and doesn't help your current sp - which is where we sit today.
It takes strong belief in what you've got to 'go-it-alone'... Others would have sold out. So as you are looking at the hammered sp of today do not forget that we are sitting on a powder keg. Once proven, the reward to shareholders will be much higher then it would be if BP were already invited to the dance.
Of course the Amgen deal was a nice boost to sp and validated ADXS but also kept their Flagship product - in-house. Just a thought. GLTALs.
My thoughts as well James...
I believe the bottom is in folks...
Thanks Dawson! Always a good read...
Now Recruiting... Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer (AIM2CERV)
This study is currently recruiting participants:
https://clinicaltrials.gov/ct2/show/NCT02853604?term=advaxis&rank=2
Lawsuit Question: You have to ask yourself. Do you believe in this kind of coincidence? That just as the Shorts were piling on to what amounts to the nearly the highest Short interest of the year (only 3 bi-monthly counts higher). They get the gift of a perfectly timed Lawsuit.
I don't believe in those kinds of coincidences. Those that have been around long enough saw the same thing in early 2015. Following a nice run-up on great news in Dec 2014... Pearson put forth an article on SA that trashed ADXS every way he could think of. JE successfully refuted every point that he made, including how he used an incorrect slide from a presentation. This was followed up by Ambulance Chasing attorneys of all sorts. The sp tanked and the Shorts had a field day. A couple months later Longs realized what a gift that manipulation was. History repeats itself.
I just signed up. Thanks!
Did Anyone catch '60 Minutes' story on AI this past Sunday? (AI= Artificial Intelligence). Part of the story dealt with the Super Computer Watson of 'Wheel of Fortune' fame, that is being used to help Doctors decide the best course of action for Cancer patients. You can view it here (Cancer discussion start at 4:50 in video:
http://www.roboticstrends.com/article/watch_60_minutes_report_on_ai/
Of particular interest to us ADXS fans is how this Super Computer is being used to decipher patients cancer Genome/DNA make-up (or mutation). Think about how well this fits with our NEO Solution of individualized cancer treatment based on genome sequencing. Could it be that one day this computer very quickly uncovers patient genome make-up and ADXS takes it from there? Or even recommends our NEO Solution as the best course of action...
ADXS CSO invited to speak at Immune Profiling World Congress. (Dr. Petit will deliver a lecture entitled, "Realizing the promise of neoantigens: Using live attenuated bacteria to generate personalized cancer immunotherapies,")
http://www.marketwatch.com/story/advaxis-cso-invited-to-speak-at-immune-profiling-world-congress-2016-10-06